Skip to Content

Join the 'Immune Globulin Intravenous' group to help and get support from people like you.

Immune Globulin Intravenous News

CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults

Posted 21 Sep 2017 by Drugs.com

KING OF PRUSSIA, Pa. — 14 September 2017 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability. CIDP is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage. “The FDA approval of Privigen for CIDP represents a significant milestone for individuals with this debilitating and progressive disease. It is a testament to our commitment to meet the needs of patients with disabling neurologic conditions, including CIDP,” said Dr. Andrew Cuthbertson, chief scientific officer and director of Research and Development for CSL Limited. “As we focus on building a leading neurology franchise, we continue to ... Read more

Related support groups: Immune Globulin Intravenous, Privigen, Chronic Inflammatory Demyelinating Polyradiculoneuropathy

'Immunotherapy' in Monkeys Shows Promise as Long-Term HIV Treatment

Posted 13 Mar 2017 by Drugs.com

MONDAY, March 13, 2017 – Lab experiments with monkeys suggest that "immunotherapy" holds promise as a long-term treatment for HIV, researchers say. Treatment with two anti-HIV antibodies right after infection might help keep the AIDS-causing virus in check for a prolonged period, according to the new study. Despite an arsenal of HIV drugs, effective long-term treatment remains elusive because inactive versions of the virus lie in wait for an opportunity to attack the immune system, said the researchers from Rockefeller University in New York City and the U.S. National Institutes of Health. "This [new] form of therapy can induce potent immunity to HIV, allowing the host to control the infection," said Michel Nussenzweig, head of Rockefeller's laboratory of molecular immunology. "It works by taking advantage of the immune system's natural defenses, similar to what happens in some forms ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Hizentra, RhoGAM, Immune Globulin Intravenous, Gamunex, Gammagard, Hepatitis B Immune Globulin, Privigen, Diagnosis and Investigation, Vivaglobin, Rhophylac, Synagis, Gamunex-C, Carimune, Sandoglobulin, Hyqvia, MICRhoGAM, Immune Globulin Subcutaneous, Nabi-HB

Health Tip: Could Allergy Shots Help You?

Posted 21 Feb 2017 by Drugs.com

-- If you have allergies, regular shots (immunotherapy) are designed to make you less sensitive to allergens over time. The American Academy of Allergy, Asthma and Immunology says you may be a candidate for allergy shots if: Your symptoms are moderate-to-severe and your allergy season lasts a few months or more. You want to avoid long-term use of allergy medications. You can commit the time needed for getting regular allergy shots. You can afford the cost of allergy shots and related medical visits. Read more

Related support groups: Allergic Reactions, Allergies, Benadryl, Hydroxyzine, Zyrtec, Promethazine, Claritin, Loratadine, Allegra, Diphenhydramine, Allergic Rhinitis, Phenergan, Cetirizine, Hay Fever, Vistaril, Cyproheptadine, Atarax, Fexofenadine, Periactin, Xyzal

FDA Approves Biotest's Bivigam, an Intravenous Immune Globulin (Human), 10% Liquid

Posted 29 Dec 2012 by Drugs.com

DREIEICH, Germany and BOCA RATON, Fla., Dec. 20, 2012 /PRNewswire/ – Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for Bivigam for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA). Bivigam is the first polyspecific intravenous immune globulin manufactured in the U.S. by Biotest Pharmaceuticals Corporation (BPC) at its Boca Raton, Florida facility. This product is being produced for patients in the United States, and the company plans to begin commercial shipments shortly. Prof. Dr. Gregor Schulz , CEO of Biotest AG, said: "Biotest has made a significant commitment in the U.S. to bring a new immune globulin to individuals with primary immunodeficiency. We have invested over $50 million to create a state-of-the-art facility and have expanded our U.S. capabilities from plasma ... Read more

Related support groups: Primary Immunodeficiency Syndrome, Immune Globulin Intravenous

Densensitization Procedure Helps Hard-to-Match Kidney Recipients

Posted 27 Jul 2011 by Drugs.com

WEDNESDAY, July 27 – A combination therapy that "desensitizes" kidney transplant recipients could help hard-to-match patients find a needed kidney faster. The desensitization procedure combines the use of plasmapheresis – a machine that filters the blood plasma to remove antibodies – and low-doses of a medication called intravenous immune globulin (IVIG). The combination of these therapies improves survival rates dramatically. Eight years after receiving a transplant, survival rates were 81 percent for those who received the treatment compared to just 31 percent for people who had to stay on dialysis, new research found. "This is a huge unmet problem. There are probably as many as 30,000 people who have been exposed to foreign tissue waiting for a kidney. They're really hard to match," explained study author Dr. Robert Montgomery, director of the comprehensive transplant program at ... Read more

Related support groups: Renal Transplant, Gamunex, Immune Globulin Intravenous, Gammagard, Privigen, Carimune, Sandoglobulin, Octagam, Panglobulin NF, Gammar-P IV, Carimune NF, Venoglobulin-S 10%, Iveegam En, Gamimune, Panglobulin, Gamimune N 5%, Gammaplex, Polygam S/D, Gammagard S/D, Flebogamma

CSL Behring Receives FDA Approval to Extend Shelf Life for Privigen from 24 to 36 Months

Posted 20 Apr 2010 by Drugs.com

KING OF PRUSSIA, Pa., April 19 /PRNewswire/ – CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life for Privigen, Immune Globulin Intravenous (Human), 10% Liquid, from 24 to 36 months. The approval makes Privigen the first liquid intravenous immunoglobulin (IVIg) in the U.S. that can be stored at room temperature throughout its entire 36-month shelf life. Privigen is the first and only 10 percent liquid IVIg stabilized with proline, a naturally occurring amino-acid. The product is indicated for primary immunodeficiency (PI), a group of disorders, usually genetic, that result from a malfunction in part or all of the immune system. This condition prevents patients from fighting off infections caused by everyday germs. Privigen is also indicated for the treatment of patients ... Read more

Related support groups: Immune Globulin Intravenous, Privigen

Ask a Question

Further Information

Related Condition Support Groups

Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Chronic Lymphocytic Leukemia (CLL), Primary Immunodeficiency Syndrome, Autoimmune Neutropenia, Idiopathic (Immune) Thrombocytopenic Purpura, Bone Marrow Transplantation, Evan's Syndrome, Polymyositis / Dermatomyositis, Anti NMDA Receptor Encephalitis, Kawasaki Disease, HIV Infection, Myasthenia Gravis

Related Drug Support Groups

Gamunex, Privigen, Carimune, Sandoglobulin, Octagam, Panglobulin, Panglobulin NF, Gammar IV, Gamimune, view more... Gamimune N 10%, Gamimune N 5%, Gammagard S / D, Gammar-P IV, Flebogamma, Bivigam, Venoglobulin-S 10%, Venoglobulin-S 5%, Carimune NF, Gammaplex, Polygam S / D, Iveegam En

Immune Globulin Intravenous Patient Information at Drugs.com